Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAP, Express Scripts Receive Boston Subpoenas Related To Lupron, Prevacid

Executive Summary

TAP Pharmaceuticals is responding to a second request for documents related to Lupron and Prevacid from the Boston U.S. Attorney's Office

You may also be interested in...



PBMs Will Emerge From “Regulatory Cloud” Soon, Express Scripts Predicts

The investigations of pharmacy benefit management practices will take up to three more years to resolve, Express Scripts CFO Edward Stiften predicted during the Bear Stearns conference in New York Sept. 13

PBMs Will Emerge From “Regulatory Cloud” Soon, Express Scripts Predicts

The investigations of pharmacy benefit management practices will take up to three more years to resolve, Express Scripts CFO Edward Stiften predicted during the Bear Stearns conference in New York Sept. 13

TAP employee indictments

TAP Pharmaceuticals has placed four employees on administrative leave following indictments by Boston U.S. Attorney's Office July 16; two former employees were also indicted. The additional changes have no impact on TAP itself; the company previously agreed to an $875 mil. fine to settle charges related to its pricing and marketing practices. The Boston U.S. Attorney's Office has subpoenaed Express Scripts, Caremark and WellPoint for information regarding Lupron and Prevacid (1"The Pink Sheet" May 6, p. 14)...

Related Content

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel